Allogene Therapeutics, Inc. (ALLO): Capital Expenditures
$386.0K
Year ended 2025-12-31
$402.0K
Trailing 12 months to 2026-06-30
-57.9%
3-year compound annual growth
-64.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $386.0K | -44.4% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $694.0K | -54.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $1.52M | -70.8% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $5.19M | -75.8% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $21.45M | -67.5% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $65.96M | +29.9% | 2024-03-14, From 2020-01-01 |
| 2019-12-31 | $50.79M | n/m | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $3.23M | n/a | 2021-02-25, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $386.0K | -44.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
Compare ALLO, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗